Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00435
|
|||||
Drug Name |
Simvastatin
|
|||||
Synonyms |
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; Cholestat; Coledis; Colemin; Corolin; DRG-0320; Denan; KS-1113; L 644128-000U; Labistatin; Lipex; Lipovas; Lodales; MK 0733; MK 733; MK-0733; MK-733; MK733; Medipo; Nivelipol; Pantok; Rendapid; Simcard (TN); Simlup (TN); Simovil; Simvacor (TN); Simvast CR; Simvastatin & Primycin; Simvastatin (JAN/USP/INN); Simvastatin [USAN:INN:BAN]; Simvastatin, Compactin; Simvastatina; Simvastatina [Spanish]; Simvastatine; Simvastatine [French]; Simvastatinum; Simvastatinum [Latin]; Sinvacor; Sivastin; Synvinolin; TNP00259; Vasotenal; Zocor; Zocor (TN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; Zocord; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Hypercholesterolemia [ICD11:5C80.0] | Approved | [1] | |||
Therapeutic Class |
Anticholesteremic Agents
|
|||||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C25H38O5
|
|||||
Canonical SMILES |
CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
|
|||||
InChI |
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
|
|||||
InChIKey |
RYMZZMVNJRMUDD-HGQWONQESA-N
|
|||||
CAS Number |
CAS 79902-63-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 418.6 | Topological Polar Surface Area | 72.8 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 7 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
4.7
|
|||||
PubChem CID | ||||||
PubChem SID |
10321271
,10852028
,11113242
,11342166
,11362349
,11364611
,11367173
,11369735
,11371657
,11374383
,11377897
,11466893
,11468013
,11485617
,11486566
,11487751
,11489487
,11490485
,11492447
,11495531
,11528633
,11533326
,12013879
,12146013
,14831549
,14929313
,24724617
,25819951
,26612685
,26680673
,26759532
,34718442
,46508654
,47365442
,47440515
,47736737
,47885633
,47885634
,48110715
,48334759
,48416540
,496592
,49698671
,50086525
,50100555
,50100556
,648581
,7847500
,7980599
,8183649
|
|||||
ChEBI ID |
ChEBI:9150
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | ABCG1 | Transporter Info | ATP-binding cassette sub-family G member 1 | Substrate | [2] | |
BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [4] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
References | ||||||
1 | Simvastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. J Cardiovasc Pharmacol. 2013 Jul;62(1):90-8. | |||||
3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
4 | Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. | |||||
5 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.